Surfactant-Lubricated PDE4 Inhibitor Capsules for Improved Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of PDE4 inhibitors do not provide optimal dissolution properties for effective treatment of central nervous system disorders.
Innovation Solution
A capsule or granule formulation comprising a PDE4 inhibitor compound represented by Formula (I) and a surfactant, particularly sucrose fatty acid ester, is developed to enhance dissolution properties, replacing traditional lubricants like magnesium stearate with the surfactant acting as a lubricant.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If traditional lubricants like magnesium stearate are used in capsule formulation, then manufacturing processability is improved, but dissolution properties deteriorate
Solution Approach 1:
The patent changes the chemical parameters of the lubricant from traditional magnesium stearate to surfactants with specific HLB values (3-13). This parameter change allows the lubricant to maintain manufacturing processability while improving dissolution properties through surfactant-mediated wetting and dispersion of the PDE4 inhibitor particles.
Solution Approach 2:
The patent creates a composite lubricant system by combining surfactants with specific HLB value ranges with the PDE4 inhibitor compound. This composite approach allows the surfactant to simultaneously provide lubrication during manufacturing and enhance dissolution through its amphiphilic nature, resolving the contradiction between manufacturability and dissolution performance.
2Reliability
If surfactant is used as lubricant to improve dissolution properties, then dissolution properties are improved, but selection complexity of excipients increases
Solution Approach 1:
The patent simplifies excipient selection by establishing specific HLB value ranges (3-13) as selection criteria for surfactants. This parameter-based approach converts a complex qualitative selection process into a quantitative guideline, making it easier to select appropriate surfactants while maintaining improved dissolution properties.
Solution Approach 2:
The patent identifies surfactants that can serve multiple functions: as lubricants during manufacturing and as dissolution enhancers through their surfactant properties. This multi-functionality reduces the need for separate excipients for different purposes, simplifying the overall formulation while maintaining excellent dissolution characteristics.
3Ease of operation
If capsule size is reduced to No. 3 or smaller for better patient compliance, then ease of administration is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent changes the physical parameters of the formulation by using surfactant-based lubricants that provide better flow characteristics and reduced inter-particle friction. This allows for more precise filling of small capsule sizes (No. 3 or smaller) by improving the flow uniformity and reducing variability in fill weights, thereby meeting stringent manufacturing precision requirements.
Solution Approach 2:
The surfactant acts as an intermediary that mediates between the PDE4 inhibitor particles and the capsule filling process. By providing optimal lubrication and flow properties, the surfactant enables precise filling of small capsules, bridging the gap between reduced capsule size and manufacturing precision requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation exhibits excellent dissolution properties, improving the efficacy of PDE4 inhibitors for treating central nervous system disorders such as Alzheimer's disease and Parkinson's disease.
Implementation Method 1
a capsule or granule formulation comprising a compound represented by Formula (I) or the like and a surfactant
Implementation Method 2
the capsule or granule formulation having excellent dissolution properties can be produced by using a surfactant
Implementation Method 3
the surfactant is included as a lubricant
Data Source
Figure 1
AI summary
A capsule or granule formulation comprising: a compound represented by Formula (I): a pharmaceutically acceptable salt thereof, or a solvate thereof is provided. When the capsule or granule formulation comprises a surfactant, the capsule or granule formulation comprising the compound represented by Formula (I), having excellent dissolution properties is provided.